ImmunoGen Collaborates with Takeda to Develop and Commercialize Elahere to Treat Platinum-Resistant Ovarian Cancer in Japan
August 28, 2023
ImmunoGen Entered into a Multi-Target License and Option Agreement with ImmunoBiochem to Develop Antibody-Drug Conjugates
July 24, 2023
ImmunoGen Reports P-III Trial (MIRASOL) Results of Elahere (mirvetuximab soravtansine) for FRα-Positive Platinum-Resistant Ovarian...
May 5, 2023
ImmunoGen Signs a Multi-Target License and Option Agreement with Vertex to Develop Novel Targeted Conditioning Agents
March 2, 2023
Insights+: Breakthrough Therapy Designation by the US FDA in 2020
March 11, 2021
PharmaShots Weekly Snapshot (Oct 19 - 23, 2020)
October 23, 2020
Back to Home
Incisive News in 3 Shots.
First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
Terms of Service
Copyright © 2023 PharmaShots - All Rights Reserved.